Form 4: Revolution Medicines COO Sells Shares for Tax Obligations Under 10b5-1 Plan

Revolution Medicines, Inc.'s Chief Operating Officer, Margaret A. Horn, sold 3,510 shares of common stock on June 16, 2025, at a weighted average price of $39.83, to cover tax withholding obligations related to RSU vesting.

Summary

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (RVMD), sold 3,510 shares of the company's common stock.
• The transaction occurred on June 16, 2025, at a weighted average sale price of $39.83 per share.
• This sale was executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on May 31, 2023.
• The primary purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Ms. Horn beneficially owns 150,675 shares, which includes 652 shares acquired through the Employee Stock Purchase Plan on May 31, 2025, and 79,776 RSUs.

Sentiment

Score: 5

Explanation: The transaction is a routine sale by an executive to cover tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan. This is a common and expected event and does not indicate a change in the executive's view of the company's prospects. The underlying RSU vesting is a positive for the executive, but the sale itself is neutral.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating a pre-planned and non-discretionary transaction.
• The sale's purpose was to cover tax withholding obligations, which is a routine and expected event for executives receiving equity compensation.
• The underlying event, the vesting of Restricted Stock Units (RSUs), represents a positive compensation event for the executive.
• The reporting person retains a significant beneficial ownership of 150,675 shares and 79,776 RSUs, demonstrating continued alignment with shareholder interests.

Negatives

• The sale of 3,510 shares by a Chief Operating Officer reduces the direct equity holdings of a key executive.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where Revolution Medicines operates.

Stakeholder Impact

• Shareholders: A minor increase in the public float due to the sale of 3,510 shares, which is unlikely to have a material impact on the share price given the routine nature and small volume relative to total shares outstanding.
• Employees: The vesting of RSUs and subsequent tax withholding sale is a standard part of executive compensation, reflecting the company's compensation practices.

Key Dates

Keywords

Revolution Medicines, RVMD, Margaret A. Horn, Chief Operating Officer, COO, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Restricted Stock Units, RSU, Tax Withholding, Equity Compensation